The contraindications for combining lacosamide with other medications vary and require careful consideration. Lacosamide, approved for the treatment of partial-onset seizures and diabetic neuropathic pain, is known to interact with several drugs, particularly those affecting the heart rhythm and the cytochrome P450 enzyme system [1] [2].

One of the primary concerns is the potential for increased risk of cardiac arrhythmias due to the pro-arrhythmic effects of lacosamide [3]. Studies suggest that concomitant use of lacosamide with other medications that prolong the QT interval, such as certain anti-arrhythmic medications, certain medications used to treat depression, or certain antibiotics, may increase the risk of these cardiac complications [4].

Regarding medications that affect the cytochrome P450 (CYP) enzyme system, lacosamide is primarily metabolized through CYP3A4 and CYP2C19 [5]. As such, medications that inhibit these enzymes, such as certain antibiotics or antifungals, may lead to increased plasma concentrations and higher risk of lacosamide-related adverse effects [6]. Conversely, medications that induce these enzymes, such as certain anticonvulsants or anti-epileptic drugs, may decrease lacosamide concentrations, potentially reducing its efficacy [7].

Moreover, patients taking medications that affect the kidneys, such as diuretics, may require more frequent monitoring of renal function due to potential interactions with lacosamide [8].

For patients taking central nervous system (CNS) depressants, such as sedatives or benzodiazepines, concurrent use of lacosamide may add to its sedative effects, increasing the risk of CNS depression [9].

According to the FDA-approved labeling, lacosamide is contraindicated in patients with known or suspected history of hypersensitivity to lacosamide [10]. Furthermore, lacosamide should not be used in patients with certain conditions, including those with cardiac conditions such as heart failure, cardiomyopathy, or QT interval prolongation, or those with liver function impairment [11].

DrugPatentWatch.com provides a comprehensive database of drug information, patents, and regulatory approvals, offering valuable insights into the safety and efficacy of medications, including lacosamide [12].

Sources:

[1] FDA. (2008). Vimpat (lacosamide) Tablets and Oral Solution [Prescribing Information].

[2] UCB, Inc. (n.d.). Vimpat (lacosamide) tablets and oral solution. Retrieved from https://www.ucb.com/product/vimpats/

[3] Kudla, P., et al. (2014). The effect of lacosamide on the QT interval in healthy subjects: A randomized, double-blind, placebo-controlled study. Epilepsy & Behavior, 34, 246-253.

[4] Bialer, M., et al. (2009). Pharmacological properties of lacosamide, a new antiepileptic drug. Epilepsy Res, 87(2-3), 241-255.

[5] Kock, M. D., et al. (2010). Pharmacokinetics of lacosamide. Epilepsy Res, 90(1-2), 15-25.

[6] Eiermann, B., et al. (2010). Effects of concurrent medications on lacosamide pharmacokinetics in healthy male volunteers. Clinical Drug Investigation, 30(12), 731-741.

[7] UCB, Inc. (n.d.). Vimpat (lacosamide) tablets and oral solution [Prescribing Information].

[8] FDA. (2008). Vimpat (lacosamide) Tablets and Oral Solution [Prescribing Information].

[9] UCB, Inc. (n.d.). Vimpat (lacosamide) tablets and oral solution. Retrieved from https://www.ucb.com/product/vimpats/

[10] UCB, Inc. (n.d.). Vimpat (lacosamide) tablets and oral solution. Retrieved from https://www.ucb.com/product/vimpats/

[11] FDA. (2008). Vimpat (lacosamide) Tablets and Oral Solution [Prescribing Information].

[12] DrugPatentWatch.com (n.d.). Retrieved from https://www.drugpatentwatch.com